Pierpaolo Pastina

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients

Cirino Botta, Vito Barbieri, Domenico Ciliberto et al. · Cancer Biology & Therapy · 2013 · 92 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients

EC Martino, Gabriella Misso, Pierpaolo Pastina et al. · Cell Death Discovery · 2016 · 92 citations · Full text

Medicine, Immunology, Oncology +15

Radiomics predicts survival of patients with advanced non‑small cell lung cancer undergoing PD‑1 blockade using Nivolumab

Valerio Nardone, Paolo Tini, Pierpaolo Pastina et al. · Oncology Letters · 2019 · 70 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT

Valerio Nardone, Paolo Tini, Christophe Nioche et al. · La radiologia medica · 2018 · 62 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab

Rocco Giannicola, Graziella D’Arrigo, Cirino Botta et al. · Molecular and Clinical Oncology · 2019 · 52 citations · Full text

Life Sciences, Immunology, Oncology +17